NCT03077542View on ClinicalTrials.gov

Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

April 6, 2017

Primary Completion Date

July 27, 2023

Study Completion Date

August 31, 2026

Conditions
Sickle Cell Disease
Interventions
PROCEDURE

haploidentical stem cell transplant

haploidentical stem cell transplant

DRUG

Sirolimus

conditioning regimen

DRUG

Alemtuzumab

conditioning regimen

DRUG

Pentostatin

conditioning regimen

DRUG

Cyclophosphamide

conditioning regimen

DRUG

Hydroxyurea

conditioning regimen

DRUG

Filgrastim

A haploidentical relative donor will receive filgrastim (G-CSF) 10 to 16 µg/kg/d subcutaneously or intravenously for up to 6 days with apheresis collections of peripheral blood hematopoietic progenitor cells (PBPC) after the 5th day (and after the 6th day if required).

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT03077542 - Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease | Biotech Hunter | Biotech Hunter